GisselbrechtC, HaiounC, LepageE et al.. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin’s lymphoma: factors influencing chemotherapy administration. Groupe d’Etude des Lymphomes de l’Adulte. Leuk Lymphoma1997;25:289–300.
GisselbrechtCHaiounCLepageE. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin’s lymphoma: factors influencing chemotherapy administration. Groupe d’Etude des Lymphomes de l’Adulte. Leuk Lymphoma 1997;25:289–300.
)| false
Timmer-BonteJN, de BooTM, SmitHJ et al.. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol2005;23:7974–7984.
Timmer-BonteJNde BooTMSmitHJ. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol 2005;23:7974–7984.
)| false
VogelCL, WojtukiewiczMZ, CarrollRR et al.. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol2005;23:1178–1184.
VogelCLWojtukiewiczMZCarrollRR. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178–1184.
)| false
BuiBN, ChevallierB, ChevreauC et al.. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol1995;13:2629–2636.
BuiBNChevallierBChevreauC. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol 1995;13:2629–2636.
)| false
ChevallierB, CholletP, MerroucheY et al.. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol1995;13:1564–1571.
ChevallierBCholletPMerroucheY. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995;13:1564–1571.
)| false
CrawfordJ, OzerH, StollerR et al.. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med1991;325:164–170.
CrawfordJOzerHStollerR. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164–170.
)| false
GatzemeierU, KleisbauerJP, DringsP et al.. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol2000;23:393–400.
GatzemeierUKleisbauerJPDringsP. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol 2000;23:393–400.
)| false
MuhonenT, JantunenI, PertovaaraH et al.. Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. Am J Clin Oncol1996;19:232–234.
MuhonenTJantunenIPertovaaraH. Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. Am J Clin Oncol 1996;19:232–234.
)| false
OsbyE, HagbergH, KvaloyS et al.. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood2003;101:3840–3848.
OsbyEHagbergHKvaloyS. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003;101:3840–3848.
)| false
PettengellR, GurneyH, RadfordJA et al.. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood1992;80:1430–1436.
PettengellRGurneyHRadfordJA. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood 1992;80:1430–1436.
)| false
ZinzaniPL, PavoneE, StortiS et al.. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin’s lymphoma. Blood1997;89:3974–3979.
ZinzaniPLPavoneEStortiS. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin’s lymphoma. Blood 1997;89:3974–3979.
)| false
DoorduijnJK, van der HoltB, van ImhoffGW et al.. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin’s lymphoma. J Clin Oncol2003;21:3041–3050.
DoorduijnJKvan der HoltBvan ImhoffGW. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2003;21:3041–3050.
)| false
FossaSD, KayeSB, MeadGM et al.. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol1998;16:716–724.
FossaSDKayeSBMeadGM. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998;16:716–724.
)| false
CitronML, BerryDA, CirrincioneC et al.. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol2003;21:1431–1439.
CitronMLBerryDACirrincioneC. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431–1439.
)| false
PfreundschuhM, TrumperL, KloessM et al.. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood2004;104:634–641.
PfreundschuhMTrumperLKloessM. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634–641.
)| false
BohliusJ, ReiserM, SchwarzerG, EngertA. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev2004:CD003189.
BohliusJReiserMSchwarzerGEngertA. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2004:CD003189.
)| false
SungL, NathanPC, AlibhaiSM et al.. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med2007;147:400–411.
SungLNathanPCAlibhaiSM. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007;147:400–411.
)| false
ClarkOA, LymanGH, CastroAA et al.. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol2005;23:4198–4214.
ClarkOALymanGHCastroAA. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005;23:4198–4214.
)| false
KudererNM, DaleDC, CrawfordJ, LymanGH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol2007;25:3158–3167.
KudererNMDaleDCCrawfordJLymanGH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158–3167.
)| false
LymanGH, KudererNM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol2004;50:129–146.
LymanGHKudererNM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 2004;50:129–146.
)| false
CoslerLE, Eldar-LissaiA, CulakovaE et al.. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. Pharmacoeconomics2007;25:343–351.
CoslerLEEldar-LissaiACulakovaE. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. Pharmacoeconomics 2007;25:343–351.
)| false
DoorduijnJK, BuijtI, van der HoltB et al.. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin’s lymphoma. Haematologica2004;89:1109–1117.
DoorduijnJKBuijtIvan der HoltB. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin’s lymphoma. Haematologica 2004;89:1109–1117.
)| false
Eldar-LissaiA, CoslerLE, CulakovaE, LymanGH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health2008;11:172–179.
Eldar-LissaiACoslerLECulakovaELymanGH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 2008;11:172–179.
)| false
NumnumTM, KimballKJ, RocconiRP et al.. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma—a cost-effectiveness analysis. Int J Gynecol Cancer2007;17:1019–1024.
NumnumTMKimballKJRocconiRP. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma—a cost-effectiveness analysis. Int J Gynecol Cancer 2007;17:1019–1024.
)| false
Timmer-BonteJN, AdangEM, TermeerE et al.. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. J Clin Oncol2008;26:290–296.
Timmer-BonteJNAdangEMTermeerE. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. J Clin Oncol 2008;26:290–296.
)| false
U.S. Food and Drug Administration. FDA filgrastim and pegfilgrastim labels.Available at: http://www.fda.gov/cder/foi/label/2006/103353s5086LBL.pdf and http://www.fda.gov/cder/foi/label/2007/125031s082lbl.pdf. Accessed October 29, 2008.
U.S. Food and Drug Administration. FDA filgrastim and pegfilgrastim labels. Available at: http://www.fda.gov/cder/foi/label/2006/103353s5086LBL.pdf and http://www.fda.gov/cder/foi/label/2007/125031s082lbl.pdf. Accessed October 29, 2008.
)| false
MartinWG, RistowKM, HabermannTM et al.. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol2005;23:7614–7620.
MartinWGRistowKMHabermannTM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 2005;23:7614–7620.
)| false
TigueCC, McKoyJM, EvensAM et al.. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant2007;40:185–192.
TigueCCMcKoyJMEvensAM. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007;40:185–192.
)| false
AaproMS, CameronDA, PettengellR et al.. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer2006;42:2433–2453.
AaproMSCameronDAPettengellR. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433–2453.
)| false
SmithTJ, KhatcheressianJ, LymanGH et al.. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol2006;24:3187–3205.
SmithTJKhatcheressianJLymanGH. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187–3205.
)| false
CrawfordJ, DaleDC, LymanGH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer2004;100:228–237.
CrawfordJDaleDCLymanGH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228–237.
)| false
AzoulayE, AttalahH, HarfA et al.. Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Systematic review of clinical case reports and experimental data. Chest2001;120:1695–1701.
AzoulayEAttalahHHarfA. Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Systematic review of clinical case reports and experimental data. Chest 2001;120:1695–1701.
)| false
EvensAM, CilleyJ, OrtizT et al.. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol2007;137:545–552.
EvensAMCilleyJOrtizT. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007;137:545–552.
)| false
ChrischillesE, DelgadoDJ, StolshekBS et al.. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin’s lymphoma. Cancer Control2002;9:203–211.
ChrischillesEDelgadoDJStolshekBS. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin’s lymphoma. Cancer Control 2002;9:203–211.
)| false
LymanGH, DelgadoDJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer2003;98:2402–2409.
LymanGHDelgadoDJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003;98:2402–2409.
)| false
LymanGH, MorrisonVA, DaleDC et al.. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma2003;44:2069–2076.
LymanGHMorrisonVADaleDC. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003;44:2069–2076.
)| false
MorrisonVA, PicozziV, ScottS et al.. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin’s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma2001;2:47–56.
MorrisonVAPicozziVScottS. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin’s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2001;2:47–56.
)| false
LymanGH, DaleDC, CrawfordJ. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol2003;21: 4524–4531.
LymanGHDaleDCCrawfordJ. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21: 4524–4531.
)| false
LymanGH, DaleDC, FriedbergJ et al.. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol2004;22:4302–4311.
LymanGHDaleDCFriedbergJ. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 2004;22:4302–4311.
)| false
BerghmansT, PaesmansM, LafitteJJ et al.. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer2002;10:181–188.
BerghmansTPaesmansMLafitteJJ. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 2002;10:181–188.
)| false
Garcia-CarboneroR, MayordomoJI, TornamiraMV et al.. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst2001;93:31–38.
Garcia-CarboneroRMayordomoJITornamiraMV. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001;93:31–38.
)| false
JohnstonE, CrawfordJ, BlackwellS et al.. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol2000;18:2522–2528.
JohnstonECrawfordJBlackwellS. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522–2528.
)| false
KaufmanPA, ParolyW, RinaldiD. Randomized double blind phase 2 study evaluating same-day vs. next-day administration of pegfilgrastim with docetaxel, doxorubicin and cyclophosphamide (TAC) in women with early stage and advanced breast cancer SABCS [abstract]. Breast Cancer Res Treat2004;88:Abstract 1054.
KaufmanPAParolyWRinaldiD. Randomized double blind phase 2 study evaluating same-day vs. next-day administration of pegfilgrastim with docetaxel, doxorubicin and cyclophosphamide (TAC) in women with early stage and advanced breast cancer SABCS [abstract]. Breast Cancer Res Treat 2004;88:Abstract 1054.
)| false
BelaniCP, RamalingamS, Al-JanadiA et al.. A randomized double-blind phase II study to evaluate same-day vs next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with NSCLC [abstract]. J Clin Oncol2006;24(Suppl 1):Abstract 7110.
BelaniCPRamalingamSAl-JanadiA. A randomized double-blind phase II study to evaluate same-day vs next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with NSCLC [abstract]. J Clin Oncol 2006;24(Suppl 1):Abstract 7110.
)| false
StullDM, BilmesR, KimH, FichtlR. Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia. Am J Health Syst Pharm2005;62:83–87.
StullDMBilmesRKimHFichtlR. Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia. Am J Health Syst Pharm 2005;62:83–87.
)| false
DaleDC, BonillaMA, DavisMW et al.. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood1993;81:2496–2502.
DaleDCBonillaMADavisMW. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993;81:2496–2502.
)| false
